Verve Therapeutics (NASDAQ:VERV) Now Covered by Analysts at Stifel Nicolaus

Equities researchers at Stifel Nicolaus started coverage on shares of Verve Therapeutics (NASDAQ:VERV) in a report released on Thursday, PriceTargets.com reports. The brokerage set a “hold” rating and a $58.00 price target on the stock. Stifel Nicolaus’ price target indicates a potential upside of 21.01% from the company’s previous close.

Several other brokerages have also recently issued reports on VERV. William Blair restated a “buy” rating on shares of Verve Therapeutics in a research report on Thursday, September 2nd. Jefferies Financial Group started coverage on shares of Verve Therapeutics in a research report on Monday, July 12th. They set a “buy” rating and a $72.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of Verve Therapeutics in a research report on Monday, July 12th. They set a “neutral” rating and a $50.00 price objective for the company. Finally, Guggenheim started coverage on shares of Verve Therapeutics in a research report on Monday, July 12th. They set a “buy” rating and a $84.00 price objective for the company. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Verve Therapeutics currently has a consensus rating of “Buy” and an average price target of $71.20.

Shares of NASDAQ VERV opened at $47.93 on Thursday. Verve Therapeutics has a 52-week low of $29.50 and a 52-week high of $78.00. The company has a 50 day simple moving average of $62.13.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings results on Thursday, August 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($1.60). Equities research analysts predict that Verve Therapeutics will post -0.35 earnings per share for the current year.

A number of large investors have recently bought and sold shares of VERV. FMR LLC acquired a new stake in Verve Therapeutics in the second quarter worth $207,851,000. Redmile Group LLC bought a new position in shares of Verve Therapeutics in the second quarter valued at $116,676,000. JPMorgan Chase & Co. bought a new position in shares of Verve Therapeutics in the second quarter valued at $55,446,000. RA Capital Management L.P. bought a new position in shares of Verve Therapeutics in the second quarter valued at $53,037,000. Finally, Citadel Advisors LLC bought a new position in shares of Verve Therapeutics in the second quarter valued at $48,701,000. Institutional investors and hedge funds own 55.59% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.

Featured Story: Liquidity

Analyst Recommendations for Verve Therapeutics (NASDAQ:VERV)

Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.